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The extracellular-regulated kinase (ERK) signaling pathway plays
important roles in regulating the malignant potential of cancer
cells in vitro. However, the effect of ERK signaling on the prognosis
of human tumors is not clearly understood. The present study
examined the expression of phosphorylated ERK1/2 (p-ERK1/2) as
a hallmark of ERK activation, in relation to KRAS and BRAF mutations,
in 63 endometrial cancer specimens with endometrioid-subtype,
in order to clarify the prognostic value of p-ERK1/2 expression.
Immmunohistochemical analysis revealed that 40 tumors (63%)
expressed p-ERK1/2, with varying levels of expression. Total ERK1/2
expression was also evaluated in a subset of tumors; most cases
expressed ERK1/2 constitutively but no correlation was observed
with p-ERK expression, indicating that p-ERK1/2 staining was
not due to ERK overexpression but to hyperactivation of ERK1/2.
There was no statistically significant correlation between p-ERK1/2
expression and clinicopathological features, including patient age,
International Federation of Gynecology and Obstetrics stage,
pathological grade, myometrial invasion and lymph node metastasis.
Sequencing analysis indicated that 23% of patients had a mutation
in exon 1 of KRAS, whereas none of the patients had a mutation in
exons 11 or 15 of BRAF, which are reportedly hot spots for mutation
in many tumor types. There was no significant correlation between
KRAS or BRAF status and p-ERK1/2 expression. Unexpectedly, patients
with low p-ERK1/2 expression had significantly lower relapse-free
survival (P = 0.041) and overall survival (P = 0.020). Multivariate
Cox regression analysis indicated that p-ERK1/2 expression was
an independent prognostic indicator for overall survival (P = 0.047).
These findings suggest that ERK activation occurs in a KRAS- and
BRAF-independent manner in endometrial cancer, and is associated
with favorable prognosis. (Cancer Sci 2007; 98: 652–658)
Adenocarcinoma of the endometrium is the most commongynecological malignancy in the USA. In Japan, it is the
second most common gynecological cancer, but its frequency
has increased dramatically in the last decade. Although there are
well-established surgical and chemotherapeutic treatments for
endometrial cancer, the need for molecular-target therapy has
increased, especially for recurrent disease that has acquired radio-
or chemoresistance; thus, there is a need for a better understanding
of the molecular pathways of endometrial carcinogenesis. Several
genetic alterations are reportedly associated with endometrial
carcinogenesis, and the most frequent genetic abnormalities in
cases of endometrial carcinogenesis are mutations in PTEN and
KRAS.(1–5) A PTEN mutation activates the phosphatidylinositol-
3-kinase (PI3K) pathway, and a KRAS mutation activates the
extracellular-regulated kinase (ERK)–mitogen-activated protein
kinase (MAPK) pathways; both mutations activate nuclear down-
stream targets and play major roles in most human carcinogenesis.(6)
The ERK–MAPK pathway is activated by mitogenic stimuli
mediated by receptor tyrosine kinases and G protein-coupled
receptors, leading to sequential phosphorylation of Ras, Raf,
MAP kinase-ERK kinase (MEK) and ERK1/2. Phosphorylated
ERK1/2 translocates to the nucleus and regulates a range of
substrates (including the Ets and activator protein1/activating
transcription factor (Ap1/ATF) families of transcription factors)
that promote cell proliferation, motility, differentiation and
survival.(7–9) Thus, expression of phosphorylated ERK1/2 (p-
ERK1/2) is the hallmark of activated MAPK signaling. To our
knowledge, there have been no reports of studies on the
expression of p-ERK1/2 in endometrial cancers.
A mutation in KRAS induces continuous activation of the
ERK pathway, even in the absence of mitogenic stimuli, and
is thought to play a critical role in carcinogenesis of various
organs.(6) Recently, we found that this KRAS mutation plays a
causative role in endometrial carcinogenesis, using an in vitro
model in which human endometrium-derived immortalized cells
were transfected with mutated KRAS alleles and were found to
exhibit completely transformed phenotypes.(10,11)
In contrast to the results of those in vitro studies, genetic
analyses by us and other researchers using clinical samples of
endometrial cancer have identified the KRAS mutation only in
10–20% of patients.(2–5) This discrepancy gives rise to several
questions. Is MAPK signaling activated in only a small subset
of endometrial cancers? Does the KRAS mutation inevitably
confer activated MAPK signaling? Recent genetic studies indi-
cate that frequent genetic mutations of BRAF in a wide variety
of tumor types are etiological factors in activation of the MAPK
pathway. However, the status of BRAF and the role of its muta-
tion in activating MAPK pathways in endometrial cancer remain
controversial.
In the present study, we analyzed expression of p-ERK1/2 in
relation to the mutation status of KRAS and BRAF in endometrial
cancer. The present findings clearly indicate that the ERK–MAPK
pathway was frequently activated, independent of the status of
KRAS and BRAF. Furthermore, we obtained the novel finding
that p-ERK1/2 expression appears to have a favorable effect on
patient survival.
Materials and Methods
Patient and tissue samples. A total of 63 patients with
endometrioid-type endometrial cancer (mean age, 57.5 years;
range, 32–78 years) treated at the Department of Obstetrics and
Gynecology, Kanazawa University Hospital, from January 1995
to December 2002, were enrolled for the study. All patients
underwent a total abdominal or radical hysterectomy plus bilateral
salpingo-oophorectomy. Systemic retroperitoneal lymphadenectomy
was carried out in approximately 70% of the patients. Staging
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was done for all patients using the International Federation of
Gynecology and Obstetrics (FigO) surgical staging system: 46
tumors were classified as stage I (substages: Ia, 10 tumors; Ib,
28 tumors; Ic, eight tumors); six tumors were classified as stage
II (substages: IIa, three tumors; IIb, three tumors); nine tumors
were classified as stage III (substages: IIIa, three tumors; IIIc,
six tumors); and two tumors were classified as stage IV. Based
on histological examination, 34 tumors were classified as G1,
14 tumors were classified as G2, and 15 tumors were classified
as G3. Patients with risk factors for recurrence (such as deep
myometrial invasion, cervical involvement, special histology or
positive peritoneal cytology) underwent external radiotherapy
and/or 4–6 cycles of CAP chemotherapy (cisplatin 90 mg/m2;
doxorubirin 50 mg/m2; cyclophosphamide 500 mg/m2) or TJ
chemotherapy (paclitaxel, 180 mg/m2; carboplatin, according
to Chatelut’s formula [area under curve = 5 mg/ml/mL]) as a
postoperative adjuvant therapy. Patient treatment was followed
up with a gynecological examination, recording of laboratory
data, transvaginal/abdominopelvic ultrasonography, and a
radiologic examination. Data from regular follow-up visits to
the outpatient department were stored in a database specifically
designed for endometrial carcinoma patients. A telephone
survey to update the status of all surviving patients was made in
August 2004. The exact date of disease recurrence was defined
as the date when the apparent tumors were detected by
ultrasonographic or radiologic examinations.
Tumor samples were collected at the time of surgery, with
written informed consent and approval of the Ethics Committee
of Kanazawa University. Half of each tissue sample was exam-
ined histologically by pathologists, and the remaining portion
of each sample was frozen at −80°C until DNA extraction for
mutation analysis.
Western blot analysis. To verify the validity of the antibody, an
in vitro induction experiment for p-ERK1/2 was carried out
using immortalized endometrial epithelial cells (EM-E6/E7/TERT)
with or without oncogenic mutant KRAS alleles.(10,11) The cells
were incubated with or without epidermal growth factor (EGF),
or were incubated with specific inhibitors of MEK (U0126),
PI3K (wortmannin) and p38 (SB203580) for 15 min. After
incubation, cell lysates were extracted and used for western blot
analysis to visualize phosphorylated ERK. Whole-cell lysates
were prepared by resuspending cell pellets in buffer containing
50 mM Tris-Cl (pH 7.4), 1% Nonidet P40 (Fluka), and 1 mM
ethylenediaminetetracetic acid for 10 min at room temperature.
The homogenate was centrifuged at 8000 g for 5 min. The
supernatant was recovered, and its protein concentration was
measured by Bradford assay. Then, 30 µg of extract was
electrophoresed on a sodium dodecylsulfate–polyacrylamide gel
with a gradient of 10–20% (Readygels J, 161-J351, Bio-Rad),
and was transferred to a polyvinylidine difluoride membrane.
Membranes were blocked with TBS-T (150 mM NaCl, 20 mM
Tris-Cl [pH 7.5], 0.1% Tween) containing 5% non-fat powdered
milk, and were then incubated with specific primary antibody
against p-ERK1/2 or total ERK1/2, followed by incubation with
horseradish peroxidase-linked antirabbit IgG. Immunoreactive
bands were visualized using the ECL detection system (Amersham),
according to the manufacturer’s instructions.
Immunohistochemistry. Immunohistochemical analysis of p-
ERK1/2 and total ERK1/2 was carried out using formalin-fixed,
paraffin-embedded specimens of endometrial cancer tissue.
The primary antibody for phosphorylated ERK1/2 was rabbit
monoclonal phosphor-p44/42 MAPK (Thr202/Tyr204) antibody
(Cell Signaling Technology), which detects endogenous levels
of human p42 and p44 MAP kinase (ERK1 and ERK2) only
when they are phosphorylated at Thr202 and Tyr204, respectively.
The antibody used for total ERK1/2 was rabbit polyclonal
p44/42 MAPK antibody (Cell Signaling Technology), which
detects endogenous levels of human p42 and p44 MAP kinase.
Neither of these antibodies crossreacts with JNK/SAPK or p38
MAP kinase.
After specimens were deparaffinized in xylene and graded
alcohols, epitope retrieval was done. The sections were heated
in a microwave oven at 700 W for 10 min in 1 × Antigen Retrieval
Solution (Biogenex). Then, endogenous peroxidase was blocked
by immersing the sections in 0.3% H2O2 methanol for 30 min.
After blocking with horse serum, the sections were incubated
for 16 h at 4°C with the (above-described) appropriate primary
antibody at 1:100 dilution. The subsequent steps were carried
out using the ABC-elite kit (Vecter Laboratories), according to
the manufacturer’s instructions. Color development used the
peroxidase substrate 3-3′-diaminobenzidine tetrahydrochloride
(DAKO Cytomation). All slides were counterstained with GM
hematoxylin stain solution (Muto Pure Chemical Co.).
As a positive control, we used sections of mouse tumors that
arose from the endometrial cell line EM-E6/E7/TERT/Ras with
an oncogenic mutant KRAS allele.(11) For negative controls, the
primary antibody was omitted. The evaluation of immunohisto-
chemistry results was carried out independently by two observers.
Staining intensity was classified into four levels: no, weak,
moderate and strong expression. Weak expression represented
faint and/or focal expression, whereas moderate and strong
expression represented significant expression at a rate of >5%
positivity for expression among tumor cells in each section.
The results of the staining were reviewed without knowledge
of the clinicopathological data by two of the coauthors (S. K.
and N. M.), who scored the percentage of positive nuclei and/or
cytoplasm within tumors. The average staining score was regis-
tered, and there was no statistically significant difference in the
scoring between observers. For the survival analysis, patients
with no expression or weak expression were assigned to the low-
expression group, and those with moderate or strong expression
were assigned to the high-expression group.
Real-time polymerase chain reaction. Total RNA was extracted
from 22 surgical tissue specimens (14 samples with low p-ERK
expression and eight samples with high p-ERK expression)
using NucleoSpin RNA II (Marchery-Nagel) and was reverse
transcribed using SuperScript II Reverse Transcriptase and oligo
(dT) primers (SuperScript First-strand Synthesis System for
RT-PCR; Invitrogen). The mRNA expression levels of the ERK1
and ERK2 genes were measured by fluorescence-based, TaqMan
real-time polymerase chain reaction (PCR), using the ABI PRISM
7000 Sequence Detection System (Applied Biosystems). Real-
time PCR was carried out with a 40-µL reaction mixture
containing 2 × TaqMan Universal PCR Master Mix (Applied
Biosystems), 20 × primer–probe mix (MAPK1, Hs00177066-m1;
MAPK3, Hs00385075-m1; Applied Biosystems). After 2 min at
50°C and 10 min at 95°C, amplification was carried out using
40 cycles of 95°C for 15 s and 60°C for 60 s. As the control,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
expression was examined. To detect GAPDH mRNA expression,
assays that measured the gene expression products of the GAPDH
gene (Applied Biosystems) were used. The amplification plot,
the graph of the increment of fluorescence reporter signal vs cycle
number during PCR, was examined early in the reaction, at a point
that represents the logarithmic phase of product accumulation.
KRAS and BRAF mutation analysis. We previously reported the
presence of KRAS mutation in endometrial cancer. In the
present study, we used a greater number of samples (44 cases) to
assay for KRAS and BRAF mutation. Exon 1 of KRAS (including
codons 12 and 13) and exons 11 and 15 of BRAF were
amplified by PCR, using DNA extracted from endometrial cancer
tissue as a template. The primer sets used for KRAS were as
follows: forward, 5′-GGTACTGGTGGAGTATTTGATAGTG-
3′; and reverse, 5′-CATGAAAATGGTCAGAGAAACC-3′.
The primer sets used for BRAF were as follows: exon 11
forward, 5′-TCCCTCTCAGGCATAAGGTAA-3′; exon 11 reverse,
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5′-CGAACAGTGAATATTTCCTTTGAT-3′; exon 15 forward,
5′-TAGGAAAGCATCTCACCTCATCC-3′; and exon 15 reverse,
5′-CACTGATTTTTGTGAATACTGGGAAC-3′. PCR products
were purified using the Qiagen PCR purification kit (Qiagen),
and direct sequencing was then carried out. PCR products with
suspected mutations were reamplified and subsequently cloned
into pGEM-T Easy (Promega), and at least three of those clones
were sequenced.
Statistical analysis. We used the χ2-test for 2 × 2 tables to
compare the categorical data. Life tables were computed using
the Kaplan–Meier method, and the Log-rank test was used to
assess statistical significance. Cox proportional hazards analysis
was used to determine the relative contribution of various factors
to the risk of recurrence. A P-value of <0.05 was considered to
indicate statistical significance. All statistical analyses were done
using the statistical package StatView version 5.0 (Abacus Concepts).
Results
Expression of phosphorylated ERK1/2 in endometrial cancer.
Figure 1 shows the results of western blot analysis to confirm
the validity of the antibody used for p-ERK1/2 immuno-
histochemistry. When the endometrial epithelium-derived cell
line (EM-E6/E7/TERT) was treated with EGF, a band of p-
ERK1/2 (p-p42/44) was clearly induced, whereas the amount of
total ERK1/2 was not altered. We also examined the expression
of p-ERK1/2 in EM-E6/E7/TERT cells with oncogenic mutant
KRAS alleles. The expression of p-ERK1/2 was significantly
upregulated in these cells. This induction was partially cancelled
by treatment with the specific MEK inhibitor U0126, but not by
the p38 inhibitor SB203580 or the PI3K inhibitor wortmannin.
These findings indicate that the main mechanism of ERK1/2
regulation upon mitogenic stimuli is its phosphorylation, and show
that the antibody we used recognizes phosphorylated ERK1/2
with sufficient sensitivity and specificity.
Expression levels of p-ERK1/2 varied widely among samples
(Fig. 2). We found that 18 samples had weak expression of
p-ERK1/2, 15 had moderate expression, and eight had strong
expression. Thus, 40 of the 63 samples (63%) had p-ERK1/2
expression. The p-ERK1/2 signals were detected mainly in nuclei
(Fig. 2c), but most samples with strong expression had both
nucleic and cytoplasmic expression (Fig. 2e–f). We also exam-
ined the expression of total ERK1/2 in a subset of 26 tumor
specimens. Homogeneous but varying levels of staining for total
ERK1/2 were observed in all 26 samples, independent of the
p-ERK1/2 status (data not shown). Furthermore, we measured
the expression levels of ERK1 or ERK2 mRNA by quantitative
RT-PCR in 22 patients whose RNA was available for the analysis,
and compared them with the status of p-ERK1/2 expression.
As shown in Fig. 3, no significant correlation was observed
between ERK1 or ERK2 mRNA expression and p-ERK1/2
expression. These findings indicate that expression of p-ERK1/2
is not the consequence of overexpression of ERK1/2 but the
result of hyperactivation of ERK1/2.
The patients were stratified into two groups depending on the
expression levels of p-ERK1/2. Patients with no or weak expres-
sion were assigned to the low-expression group, and those with
moderate or strong expression were assigned to the high-expression
group, and the relationships between p-ERK1/2 expression and
clinicopathological variables are shown in Table 1. There was
no significant correlation between p-ERK1/2 expression and
clinicopathological characteristics including patient age, FigO
staging, pathological grade, depth of myometrial invasion,
pelvic lymph node metastasis, menopause or body mass index.
Identification of KRAS and BRAF mutation and correlation with
p-ERK expression. Of the 63 samples we examined, 44 were
available for DNA sequencing. Of those 44 samples, 10 samples
had a mutation in KRAS codon 12 and/or codon 13 (Table 2).
We examined the correlation between KRAS mutation and
p-ERK1/2 expression. Seven of the 10 cancers with KRAS
mutation (70%) had p-ERK1/2 expression, whereas 24 of the
34 cancers without KRAS mutation (71%) had p-ERK1/2
expression. Thus, there was no significant correlation between
KRAS mutation and p-ERK1/2 expression. Also, exons 11 and
15 of the BRAF gene were sequenced; no mutations were detected
in any of the samples examined, and this was confirmed by
repeated sequencing of both the upper and lower strands.
Effect of p-ERK expression on prognosis of endometrial cancer.
We next examined the prognostic effect of p-ERK1/2 expression.
The mean follow-up for all patients was 4.08 years for relapse-
free survival (RFS; median, 3.51 years; range, 0.15–9.63 years)
and 4.31 years for overall survival (OS; median, 3.75 years; range,
0.56–9.63 years). First, the effect of p-ERK1/2 expression on
RFS was analyzed. Among the 63 patients, 11 patients (17.5%)
had suffered relapses of endometrial cancer at the time of the
last follow-up. Figure 4 illustrates univariate outcomes based
on p-ERK1/2 expression. The RFS for the high- and low-
expression groups were 95.7 and 75.0%, respectively (P = 0.0407).
Next, the effect of p-ERK1/2 on OS was analyzed. Among
the 63 patients, 12 patients (19.0%) had died (eight from
endometrial cancer, and four from other causes [breast cancer,
melanoma, liver cancer and lung embolism]) at the time of the
last follow-up. The OS for the high and low p-ERK1/2 expression
groups were 95.7 and 72.5%, respectively (P = 0.0203). Thus,
low p-ERK1/2 expression negatively affected RFS and OS in
univariate analysis. Among other clinicopathological factors, FigO
Fig. 1. Validation of the phosphorylated
extracellular-regulated kinase (p-ERK1/2) antibody
using western blot analysis. The endometrial
epithelium-derived cell line EM-E6/E7/TERT was
incubated with or without epidermal growth
factor (EGF) at 10 or 100 nM for 15 min, and
protein extracts were prepared and subjected to
western blot analysis to assay expression of p-
ERK1/2. EM-E6/E7/TERT cells transfected with
oncogenic mutant KRAS were used as a positive
control of p-ERK1/2 expression. Two bands (42
and 44 kDa) were found to be induced by
treatment with EGF or transfection with oncogenic
mutant KRAS, and this effect was specifically
inhibited by treatment with a MAP kinase-ERK
kinase (MEK) inhibitor (U0126), but not by a p38
(SB203580) or phosphatidylinositol-3-kinase (PI3K)
inhibitor (Wortmannin). The expression levels of
total ERK1/2 were not altered by these treatments.
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stage ≥II (P < 0.0001), myometrial invasion ≥1/2 (P = 0.0009)
and tumor grade ≥2 (P = 0.043) negatively affected RFS in
univariate analysis. Similarly, FigO stage ≥II (P = 0.0170) and
myometrial invasion ≥1/2 (P = 0.0111) negatively affected OS
in univariate analysis (Table 3).
Finally, when the above prognostic factors that affected RFS
or OS evaluated in the univariate analyses were included in a
Cox proportional-hazard analysis, only FigO stage was an inde-
pendent predictive factor for RFS (Hazard ratio 6.21, P = 0.01),
and both FigO stage (Hazard ratio 3.492, P = 0.0478) and low
p-ERK1/2 expression (Hazard ratio 8.202, P = 0.0472) were
independent predictive factors of OS (Table 3).
Discussion
In the present study, we demonstrated that the ERK–MAPK
pathway was frequently activated, independent of the status of
KRAS and BRAF, in endometrioid-type endometrial cancer. We
found that 65% of the endometrial cancers expressed p-ERK1/2,
whereas the KRAS mutation was detected in 22% of the patients,
and there was no significant correlation between KRAS mutation
and p-ERK1/2 expression. Thus, the present results indicate that
KRAS mutation is not a major determinant of ERK activation in
endometrial cancer. Alternate pathways may therefore exist for
ERK activation, such as via crosstalk with the PI3K pathway.(12)
It is likely that activation of PI3K signaling by the PTEN mutation
(which was detected in 30–40% of patients in a previous study)(5)
contributes to increased p-ERK1/2 expression via crosstalk.
However, we found that three of the 10 patients with the KRAS
mutation lacked p-ERK1/2 expression. The reason for the lack
of p-ERK1/2 expression despite KRAS mutation remains unclear.
Recently, several negative regulators of the MAPK signaling
pathway upstream of ERK were identified, including Sprouty
Fig. 2. Immunohistochemical staining of phosphory-
lated extracellular-regulated kinase (p-ERK1/2)
in endometrial cancer specimens. (a) Positive control
consisted of sections of mouse tumor that arose
from endometrial epithelial cells with an oncogenic
mutant KRAS allele (EM-E6/E7/TERT/Ras), and
exhibited significant p-ERK1/2 expression in tumor
but not in surrounding mouse tissue. (b) A sample
with negative staining. (c) A sample with weak,
focal staining classified as weak expression. (d) A
case with moderate expression. (e,f) A case with
strong expression. (a–e) ×100; (f) ×400. Black bars =
100 µm. White bar = 25 µm.
Fig. 3. Relationship between extracellular-regulated kinase (ERK1/2)
mRNA and phosphorylated ERK (p-ERK) expression in endometrial cancer
specimens. Relative levels of (a) ERK1 and (b) ERK2 mRNA expression were
measured by real-time polymerase chain reaction in 22 endometrial
cancer specimens and were compared between two groups with low
and high p-ERK expression. Bars represent mean values.
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and Spred.(13–16) Spred inhibits MAPK signaling at the level of
Raf by binding to Ras and Raf, whereas Sprouty is thought to
target Grb, Sos and Raf. Activation of these negative regulators
inhibits phosphorylation of ERK1/2, even in the presence of
the KRAS mutation. We are currently analyzing the status of
expression of these negative regulators in relation to the KRAS
mutation and p-ERK1/2 expression levels. Overall, our data
indicate that complex regulatory pathways are involved in ERK
phosphorylation in endometrial cancer, which does not necessarily
involve the KRAS mutation.
Another interesting finding of the present study is the com-
plete lack of BRAF mutation in endometrial cancer. Although an
increasing number of studies have identified mutations of BRAF
in a wide variety of cancer types,(17) there is controversy as to
whether BRAF mutations are associated with endometrial
cancer. To our knowledge, there have been four reported studies
of BRAF mutations in endometrial cancer. In three of those four
studies, no BRAF mutations or a very low frequency of BRAF
mutations was detected: one of 146 cases,(18) one of 48 cases,(19)
and none of 67 cases.(20) In the remaining study, which was
conducted in Japan, 20 of 97 endometrial cancer patients (21%)
had a BRAF mutation.(21) This discrepancy raises confusion
regarding the involvement of BRAF mutations in endometrial
carcinogenesis. The question may thus arise whether BRAF is
population-specific, especially with Japanese. However, the present
results make this unlikely, and are consistent with the three
above-described non-Japanese reports. The available evidence
indicates that BRAF mutations are not major constituents of
MAPK signaling in endometrial cancer, whereas they play a
major role in other epithelial tumors.
The novel finding we obtained in the present study is that
p-ERK1/2 expression appears to have a favorable effect on patient
survival. This is in contrast to previous in vitro data showing
that the MAPK pathway is involved in cellular proliferation and
motility. Limited investigations indicate that p-ERK expression
has prognostic significance in various tumor types, but the results
of theses studies are controversial. In salivary gland cancer, high
levels of expression of p-ERK were associated with early
progression of the tumor.(22) In breast cancer, high levels of
MAPK activity in the cytosol coincided with positive lymph node
involvement and higher risk of relapse within 40 months of
follow-up, but there was no significant correlation.(23) In con-
trast, a recent study demonstrated that high p-ERK expression in
breast cancer correlated with a low frequency of recurrence and
infrequent fatal outcome, and that high p-ERK expression was
an independent indicator of long relapse-free survival and over-
all survival in multivariate analysis.(24) Another study of breast
cancer indicates that p-ERK expression is associated with small
tumors with better survival.(19) In a study of ovarian tumors,
patients with high ERK and p-ERK expression in pleural effusions
Table 1. Associations between phosphorylated extracellular-regulated









<60 39 18 21 0.06
≥60 24 5 19
FigO stage
I 46 18 28 0.56
II-IV 17 5 12
Grade
1 34 16 18 0.07
2, 3 29 7 23
Myometrial invasion
<1/2 47 20 27 0.13
≥1/2 16 3 13
Pelvic lymph node metastasis
No 58 21 37 > 0.999
Yes 5 2 3
Menopause
Premenopausal 23 11 12 0.18
Postmenopausal 40 12 28
Body mass index
<25 38 15 23 0.60
≥25 25 8 17
†High and low mean moderate/strong expression and no/weak 
expression, respectively. ‡Fisher’s exact method.





KRAS sequence BRAF sequence 
Exon 1 Exon 11 Exon 15 
Mutation Wild type Mutation Wild type Mutation Wild type
None 13 3 10 0 13 0 13
Weak 13 4 9 0 13 0 13
Moderate 12 1 11 0 12 0 12
Strong 6 2 4 0 6 0 6
Total 44 10 34 0 44 0 44
Table 3. Prognostic analysis for overall survival
Variable Risk factor
Univariate (Kaplan–Meier) 
Log rank test (P-value)
Multivariate (Cox regression model) 
Hazard ratio (95% confidence interval)
P-value
FigO stage ≥II 0.0170 3.492 (1.012–12.049) 0.0478
Myometrial invasion ≥1/ 2 0.0111 2.341 (0.713–7.693) 0.1610
p-ERK1/ 2 expression Low 0.0203 8.202 (1.026–65.550) 0.0472
Low means no or weak expression. p-ERK1/2, phosphorylated extracellular-regulated kinase.
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had better overall survival than patients with low ERK or p-ERK
values.(25) Why do such discrepancies arise among studies
or tumor types? One possible explanation is different assay
conditions of immunohistochemistry or western blotting. For
evaluation of p-ERK expression, the type of antibody used is
critical, and validation of the antibody should be carried out
carefully. Differences between methods of lysate extraction in
western blotting may cause differences in results. ERK is
located in both the nucleus and cytosol, but is found mainly in
the nucleus. In whole-cell lysate extraction, the ratio of cytoplasmic
and nuclear fractions depends strongly on the method of extrac-
tion, which affects evaluation of expression levels. In addition,
differences in the ratio of epithelial and stromal components
in each tumor sample cause differences in the results of ERK
expression assays, which is a limitation and shortcoming of
western blot analysis.
The physiological importance of MAPK signaling is due to
the fact that it transduces signals from membrane receptors to
transcriptional machinery in the nucleus. MAPK signaling plays
pivotal roles in physiological proliferation of normal cells. In fact,
normal endometrium expresses p-ERK more frequently than
endometrial cancer, and proliferation of normal endometrium
appears to be highly dependent on MAPK signaling (Kyo S,
Hashimoto M unpublished data), indicating that p-ERK expres-
sion is required for proliferation of normal endometrium, rather
than progression of cancer cells. Cancer cells usually obtain their
own pathway for progression and may not highly depend on
such physiological signals. For example, during tumorigenesis
in estrogen-dependent organs, cancer cells are likely to lose
expression of estrogen receptors and achieve hormone-independent
growth, leading to more aggressive phenotypes, in which genetic
rearrangements such as mutation, deletion and translocation
of genes more seriously contribute to the malignant potential
of cells. This theory may be applied to p-ERK expression in
endometrial cancer.
In summary, the present results indicate that p-ERK1/2 is
frequently expressed in endometrial cancer, independent of KRAS
and BRAF status, indicating that RAS/RAF mutation is not the
main cause of MAPK signaling in this tumor type. The expres-
sion level of p-ERK1/2 is an independent prognostic indicator,
and may be useful as a clinical parameter for prediction of
patient survival. The present data raise the question of whether
molecular therapies that target the MEK–ERK pathway are
effective against endometrial cancer.
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